He is a director of the Stryker Corporation.[6] He is involved in the creation of new cancer drugs and treatments.[7] For example, Engelman is involved in research to use peptides to aid in destroying tumors.[8]
Engelman directs the Engelman Laboratory at Yale focused on the biophysics of biological membranes. His group is best known for elucidating the mechanism of pH Low Insertion Peptide (pHLIP) to form trans-membrane helices.[13][14]
Patents
Engelman holds six United States patents for his discoveries.[15]
References
^Lemmon, Mark A.; Flanagan, John M.; Treutlein, Herbert R.; Zhang, Jian; Engelman, Donald M. (1992). "Sequence specificity in the dimerization of transmembrane .alpha.-helixes". Biochemistry. 31 (51): 12719โ12725. doi:10.1021/bi00166a002. PMID1463743.
^Lemmon, Mark Andrew (1993). Specific interactions between transmembrane alpha-helices: Their role in the oligomerization of integral membrane proteins (PhD thesis). Yale University. ProQuest304065037. (subscription required)